LentiCRISPRv2-scr Citations (1)
Originally described in: Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency.Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N Sci Rep. 2019 Feb 7;9(1):1644. doi: 10.1038/s41598-018-38311-x. PubMed Journal
Articles Citing LentiCRISPRv2-scr
| Articles |
|---|
| Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway. Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A. Gynecol Oncol. 2023 Jan;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub 2022 Nov 17. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.